In a perfect world, we’d all have access to the same information, and stocks would price themselves quickly and accurately, and there’d be no “mystery” or uncertainty in taking a position.
It’s a pretty thought.
Only there is one catch – there wouldn’t be any massive opportunities like the one I’m going to show you, either.
You see, as a thrifty man, I’m always hunting for a good deal.
But the best, most satisfying, ones are always those that effortlessly fall into your lap.
And that’s exactly the kind of play that we’re going to look at.
What I’m going to show you is the next best thing to getting something for nothing.
It’s not unlike what used to happen in brick-and-mortar stores back in the day, before barcodes and RFID tags, when a high school kid would go around with a sticker gun, sticking prices on items, and make a mistake.
It might not have been so great for the employee, but it was always a sweet feeling for the consumer to get an unexpected deal.
Well, the exact same thing is happening right now in one of the best pharma companies on the market…
And it’s a “sweet deal” investors won’t want to miss out on…
Here’s what else I’m following…
Like many issues, Donald Trump has been all over the map on the legal marijuana question.
Way back in 1990, the president-elect said the United States needed to legalize all drugs and use the tax revenue to educate Americans about the dangers of drugs. (He may have been joking.)
More recently, he’s been hesitant on legal recreational marijuana but bullish on the medical kind.
“In terms of marijuana and legalization, I think that should be a state issue, state-by-state,” Trump recently told reporters. “Marijuana is such a big thing. I think medical should happen – right? Don’t we agree? I think so. And then I really believe we should leave it up to the states.”
Whatever Trump’s opinion, the overwhelming “Yes” vote on Nov. 8 just unleashed a tsunami of cash.
That tsunami is heading in the direction of marijuana companies – and in the direction of those companies’ investors.
Already, one of those medical “pot stocks” is starting to pull ahead of the pack.
That’s because it’s clear that Trump’s position on medical marijuana will boost the fortunes of companies that are working on marijuana-derived pharmaceuticals. Companies just like this one.
And you could boost your own fortune with it.
To continue reading click here.
The Internet of Everything, a vast network of devices like phones, watches, clothing and even toothbrushes – all communicating, all collecting and returning data – has been one of the biggest tech stories of the past five years.
But I’m here to tell you that it’s about to get even bigger, even more profitable, by an order of magnitude. That’s because the Internet of Everything is about to crack open the healthcare market, with small networked wearable medical, prosthetic, and therapeutic devices set to explode onto the market.
I’m talking about wearable therapeutics – or “wearapeutics.” It’s going to be a healthcare game changer.
Today, I’m showing you just how big the wearapeutics market is going to get – and the one investment you need to hold long term to get the most profits out of this exciting development.
Take a look…
A doctor injects a “corrective” gene into a virus. Then he uses that virus to introduce the new gene and modified DNA into a patient’s diseased cells. If the treatment is successful, the cells’ gene-reading machinery will build RNA messengers and protein molecules – i.e., disease fighters.
It’s a process that could be a cure for hundreds of genetic-related diseases.
That’s gene therapy in action.
When biotech researchers get gene therapy to work dependably, it will be a boon for humanity – and for investors.
For decades, Big Pharma has run on the same basic plan – use chemicals to create disease-fighting drugs. However, many of the drugs they end up creating carry severe side effects or are highly addictive.
But now, after a quarter century of failed experiments and numerous setbacks, gene therapy finally has the potential to make patients well again without addictive or harmful drugs.
Researchers worldwide report successful gene-therapy trials – and new and innovative uses for the technology – seemingly every week. The first federally approved gene therapy, the severe pancreatitis treatment Glybera, hit the market in late 2014 as. And I think the next half decade will bring dozens more gene-therapy products along those same lines.
Now, finding a way to invest in this newly disruptive biotechnology is tough. Most of the companies working on gene therapies are privately held or very risky, illiquid clinical-stage biotech companies that I just can’t recommend to beginning investors.
However, I have located a great backend way to play this breakthrough field. Its stock has soared 25% in just the past five months or so – and it shows no sign of slowing down. Plus, it pays a healthy 2% dividend.
Let me show it to you…
To continue reading click here.